Sfoglia per Autore
Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab
2008-01-01 Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Donati, S.; Fea, E.; DI DONATO, S.; Falcone, Alfredo
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
2008-01-01 Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
2008-01-01 Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
2008-01-01 Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Barletta, M. T.; Bocci, Guido; Allegrini, G.; Masi, G.; Giuntini, N.; Coltelli, L.; Bona, E.; Loupakis, F.; DI LEO, A.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; Falcone, Alfredo
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group
2008-01-01 Falcone, Alfredo; Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Amoroso, D.; Puglisi, M.; Fea, E.; Brunetti, I.
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target
2008-01-01 Pagliacci, A.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Galizia, E.; Pierantoni, C.; Loupakis, F.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, Alfredo; Cascinu, S.
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
2008-01-01 Santini, D.; Vincenzi, B.; Masi, G.; Catalano, V.; Virzi, V.; Vasile, E.; Fontana, A.; Intagliata, S.; Catalano, G.; Falcone, Alfredo; Tonini, G.
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo
Optimal approach to potentially resectable liver metastases from colorectal cancer
2008-01-01 Falcone, Alfredo; Fornaro, L.; Loupakis, F.; Masi, G.; Vasile, E.
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; DI LEO, A.; Falcone, Alfredo
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
2008-01-01 Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F.
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, Alfredo; Tonini, G.; Ruzzo, A.
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
2008-01-01 Graziano, Francesco; Ruzzo, Annamaria; Loupakis, Fotios; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Bisonni, Renato; Torresi, Umberto; Floriani, Irene; Schiavon, Gaia; Andreoni, Francesca; Maltese, Paolo; Rulli, Eliana; Humar, Bostjan; Falcone, Alfredo; Giustini, Lucio; Tonini, Giuseppe; Fontana, Andrea; Masi, Gianluca; Magnani, Mauro
Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer
2008-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Bisonni, R.; Torresi, U.; Floriani, I.; Schiavon, G.; Andreoni, F.; Maltese, P.; Rulli, E.; Humar, B.; Falcone, Alfredo; Giustini, L.; Tonini, G.; Masi, G.; Silva, R.; Magnani, M.
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
2008-01-01 Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido
Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP
2009-01-01 Masi, G.; Vasile, E.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Baldi, G.; Stasi, I.; Cupini, S.; Ciarlo, A.; DEL MONTE, F.; Trenta, P.; Mezi, S.; Rondini, M.; Andreuccetti, M.; Falcone, Alfredo
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX), and celecoxib in pretreated patients with advanced gastrointestinal cancers: A pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2009-01-01 Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fontana, A.; DI LEO, A.; Bardi, G.; Kerbel, R.; DEL TACCA, M.; Falcone, Alfredo
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
2009-01-01 Ruzzo, A.; Loupakis, F.; Canestrari, E.; Cremolini, Chiara; Vincenzi, B.; Salvatore, L.; Santini, D.; Masi, G.; Stasi, I.; Rulli, E.; Floriani, I.; Bencardino, K.; Galluccio, N.; Demidio, S.; Catalano, V.; Tonini, G.; Magnani, M.; Falcone, Alfredo; Graziano, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab | 1-gen-2008 | Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Donati, S.; Fea, E.; DI DONATO, S.; Falcone, Alfredo | |
| Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction | 1-gen-2008 | Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano | |
| First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? | 1-gen-2008 | Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo | |
| A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer | 1-gen-2008 | Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo | |
| Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Barletta, M. T.; Bocci, Guido; Allegrini, G.; Masi, G.; Giuntini, N.; Coltelli, L.; Bona, E.; Loupakis, F.; DI LEO, A.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; Falcone, Alfredo | |
| FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group | 1-gen-2008 | Falcone, Alfredo; Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Amoroso, D.; Puglisi, M.; Fea, E.; Brunetti, I. | |
| Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target | 1-gen-2008 | Pagliacci, A.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Galizia, E.; Pierantoni, C.; Loupakis, F.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, Alfredo; Cascinu, S. | |
| Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer | 1-gen-2008 | Santini, D.; Vincenzi, B.; Masi, G.; Catalano, V.; Virzi, V.; Vasile, E.; Fontana, A.; Intagliata, S.; Catalano, G.; Falcone, Alfredo; Tonini, G. | |
| Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
| Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
| Optimal approach to potentially resectable liver metastases from colorectal cancer | 1-gen-2008 | Falcone, Alfredo; Fornaro, L.; Loupakis, F.; Masi, G.; Vasile, E. | |
| Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; DI LEO, A.; Falcone, Alfredo | |
| EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach | 1-gen-2008 | Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F. | |
| High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, Alfredo; Tonini, G.; Ruzzo, A. | |
| Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer | 1-gen-2008 | Graziano, Francesco; Ruzzo, Annamaria; Loupakis, Fotios; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Bisonni, Renato; Torresi, Umberto; Floriani, Irene; Schiavon, Gaia; Andreoni, Francesca; Maltese, Paolo; Rulli, Eliana; Humar, Bostjan; Falcone, Alfredo; Giustini, Lucio; Tonini, Giuseppe; Fontana, Andrea; Masi, Gianluca; Magnani, Mauro | |
| Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer | 1-gen-2008 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Bisonni, R.; Torresi, U.; Floriani, I.; Schiavon, G.; Andreoni, F.; Maltese, P.; Rulli, E.; Humar, B.; Falcone, Alfredo; Giustini, L.; Tonini, G.; Masi, G.; Silva, R.; Magnani, M. | |
| A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. | 1-gen-2008 | Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido | |
| Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP | 1-gen-2009 | Masi, G.; Vasile, E.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Baldi, G.; Stasi, I.; Cupini, S.; Ciarlo, A.; DEL MONTE, F.; Trenta, P.; Mezi, S.; Rondini, M.; Andreuccetti, M.; Falcone, Alfredo | |
| Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX), and celecoxib in pretreated patients with advanced gastrointestinal cancers: A pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2009 | Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fontana, A.; DI LEO, A.; Bardi, G.; Kerbel, R.; DEL TACCA, M.; Falcone, Alfredo | |
| KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer | 1-gen-2009 | Ruzzo, A.; Loupakis, F.; Canestrari, E.; Cremolini, Chiara; Vincenzi, B.; Salvatore, L.; Santini, D.; Masi, G.; Stasi, I.; Rulli, E.; Floriani, I.; Bencardino, K.; Galluccio, N.; Demidio, S.; Catalano, V.; Tonini, G.; Magnani, M.; Falcone, Alfredo; Graziano, F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile